Refractory Epilepsy Clinical Trial
Official title:
Efficacy of Low Glycemic Index Diet Therapy in Children With Refractory Epilepsy - A Randomized Controlled Trial
Epilepsy is a frequent cause of morbidity in the pediatric age group. Many catastrophic epilepsies present during infancy and childhood1. Seizures in these epileptic disorders are difficult to control; sometimes only at the expense of multiple and toxic levels of antiepileptic medications. The shortcomings of antiepileptic drug therapy and epilepsy surgery warrants the need for alternative treatments. Ketogenic diet is effective for refractory epilepsies (33% of patients with refractory epilepsy have more than 50% reduction in seizures from the baseline and 15-20% become seizure free) and has gained widespread acceptance. Low glycemic index diet treatment (LGIT) is designed as a variant of ketogenic diet. There are retrospective studies on LGIT in childhood refractory epilepsy reporting seizure reduction comparable to that of patients on ketogenic diet. There have been no randomized controlled trials assessing the efficacy of the low glycemic index diet in refractory epilepsy. In this study we plan to assess the efficacy of LGIT among children with drug refractory epilepsy.
Each patient will undergo detailed clinical evaluation according to a structured proforma.
Seizure type, frequency, age at onset, perinatal details, family history, developmental
status and treatment history will be recorded. Corticosteroids or ACTH (if patient is already
on) would be tapered off 2 weeks before starting LGIT. All co-medications will be changed to
carbohydrate free preparations, wherever available only in the intervention group.
Eligible patients will be randomized in to two groups: the intervention and the control arm.
Both groups will undergo a baseline four week observation period, during which parents will
be asked to maintain a daily seizure log; recording seizure type, duration and frequency. In
the intervention arm, the children will be started on low glycemic index diet after this
4-week baseline period. The control group will receive their usual diet without any
alteration. No changes will be made to the patients' antiepileptic medication during the
4-week baseline or the 3-month study periods in both the intervention and control groups,
unless medically indicated; e.g. drug side effects, or status epilepticus; in which case
appropriate changes will be made to their medications and same will be documented. The drop
out from the intervention group will be documented along with the reason for the same. At the
end of the 3 month study period patient in the intervention arm will be continued with the
LGIT but that will not come under the purview of this study. At the end of three months study
period, patients in the control arm will be offered the option of low glycemic index diet
treatment.
Low glycemic index diet administration
1. Three day food intake by recall method will be documented
2. The calorie requirement would be calculated as per the recommended daily allowance (RDA)
for the ideal weight for that age
3. Diet regime will be explained to the parents
4. Patients (wherever applicable) and their parents will be given diet counseling
5. LGIT will be started on out patient basis.
6. Medium and high-GI carbohydrates (GI >55) will be eliminated from the diet and only food
items with low glycemic index (GI <55) will be allowed. Parent will be given a list of
low glycemic index food items33. They will also be given a list of food items (medium
and high glycemic index) which should be avoided. (Appendix)
7. Total carbohydrates intake will be restricted to 10% of caloric intake/ day (maximum
40-60 g/day).
8. Carbohydrate values of various food items will be explained in detail, and carbohydrate
exchange lists will be provided to the parent. Three to four 15 gram carbohydrate
exchanges will be allowed in a day. (Appendix)
9. Fats (e.g. cream, butter, oils and ghee) can be taken by the patient without any
restriction.
10. Proteins intake will be allowed up to 30% of the total caloric intake per day (cheese,
fish, eggs, chicken and soya products).
11. Sample menu will be discussed with the parent.
12. Clear carbohydrate free fluids will not be restricted.
Follow up Children will be reviewed as outpatients at 1, 2 and 3 months. A three day dietary
intake chart will be reviewed at each visit to compute calorie and carbohydrate intake, and
to evaluate and reinforce compliance with the prescribed diet. Weight will be checked at each
visit.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02866240 -
Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy
|
N/A | |
Withdrawn |
NCT04753983 -
A Study to Evaluate fMRI of Active DBS Stimulation in Epilepsy
|
N/A | |
Completed |
NCT01899898 -
Efficacy of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy
|
Phase 2/Phase 3 | |
Recruiting |
NCT05493722 -
Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy
|
Early Phase 1 | |
Recruiting |
NCT03062514 -
Trial to Evaluate the Safety and Effectiveness of Vagus Nerve Stimulation for Children With Refractory Epilepsy
|
N/A | |
Recruiting |
NCT04770337 -
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
|
N/A | |
Recruiting |
NCT05232630 -
Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes
|
Phase 4 | |
Completed |
NCT04545346 -
The Potential of a Low Glutamate Diet as a Treatment for Pediatric Epilepsy
|
N/A | |
Not yet recruiting |
NCT04542629 -
Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children
|
Phase 4 | |
Terminated |
NCT03570489 -
Randomized Controlled Trial on Cardiovascular Exercise in Uncontrolled Epilepsy:
|
N/A | |
Completed |
NCT05031208 -
Acute and Long Term Effects of VNS on Memory in Patients With Refractory Epilepsy
|
N/A | |
Completed |
NCT01880333 -
Evaluation of the Modified Atkins Diet in Young Children With Refractory Epilepsy
|
Phase 2/Phase 3 | |
Completed |
NCT03676569 -
Intrathecal Autologous ADRC Treatment of Autoimmune Refractory Epilepsy
|
Phase 1 | |
Withdrawn |
NCT03115489 -
Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus
|
Phase 2/Phase 3 | |
Completed |
NCT02876289 -
Retrospective Evaluation of Perampanel in a French Neurology and Epileptology Department (Hospices Civil de Lyon)
|
N/A | |
Completed |
NCT01521754 -
Product Surveillance Registry- Deep Brain Stimulation for Epilepsy
|
||
Recruiting |
NCT04684797 -
Localization of the Reward Positivity to ACC
|
N/A | |
Completed |
NCT05292183 -
Modulation of Emotion Perception in Humans Via Amygdala Stimulation
|
N/A | |
Terminated |
NCT04398667 -
European Non-interventional Study on Refractory Epilepsy With Developmental Delay
|
||
Active, not recruiting |
NCT04218812 -
Clinical Utility of Automated Electric Source Imaging in Presurgical Evaluation
|
N/A |